Work

Syk inhibitors in clinical development for hematological malignancies

Year: 2017
Type: review
Abstract: Spleen tyrosine kinase (Syk) is a cytosolic non-receptor protein tyrosine kinase (PTK) and is mainly expressed in hematopoietic cells. Syk was recognized as a critical element in the B-cell receptor signaling pathway. Syk is also a key component in signal transduction from other immune receptors like Fc receptors and adhesion receptors. Several oral Syk inhibitors including fostamatinib (R788), entospletinib (GS-9973), cerdulatinib (PRT062070), and TAK-659 are being assessed in clinical trials. The second generation compound, entospletinib, showed promising results in clinical trials against B-cell malignancies, mainly chronic lymphoid leukemia. Syk inhibitors are being evaluated in combination regimens in multiple malignancies.
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: gold
Estimated APC paid: $4,990
OpenAlex ID: W2740624719
FWCI: 2.88
Cites: 97
Cited by: 192
Related to: 10